Adalimumab-induced sensory vasculitic neuropathy

Drug Ther Bull. 2023 Sep;61(9):140-143. doi: 10.1136/dtb.2022.246401.rep. Epub 2023 Jan 17.

Authors

Nicholas Keyi Sim¹, Azzam Ismail², Taimour Alam³, Priya Devi Shanmugarajah⁴

Affiliations

¹ Department of Neurology, Calderdale and Huddersfield NHS Foundation Trust, Halifax, UK nicholas.sim1@nhs.net.
² Department of Pathology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
³ Department of Clinical Neurophysiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
⁴ Department of Neurology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.

PMID: 36649976
DOI: 10.1136/dtb.2022.246401.rep

No abstract available

Keywords: biological agents; clinical neurophysiology; peripheral nerve disease; unwanted effects / adverse reactions; vasculitis.

Publication types

Case Reports

MeSH terms

Adalimumab* / adverse effects
Humans
Neuromuscular Diseases* / chemically induced

Substances

Adalimumab